Discovery of Potent Kappa Opioid Receptor Agonists Derived from Akuammicine

Akuammicine (<b>1</b>), an alkaloid isolated from <i>Picralima nitida</i>, is an agonist of the kappa opioid receptor (κOR). To establish structure-activity relationships (SARs) for this structurally unique κOR ligand, a collection of semisynthetic derivatives was synthesized. Evaluating these derivatives for their ability to activate the κOR and mu opioid receptor (μOR) revealed key SAR trends and identified derivatives with enhanced κOR potency. Most notably, substitutions to the C10 position of the aryl ring led to a > 200-fold improvement in κOR potency and nearly complete selectivity for the κOR. A selection of the most potent ligands was shown to possess differing abilities recruitment of β-Arrestin-2 to the κOR, indicating they have distinct signaling properties from each other and existing κOR ligands. The discovery of these κOR agonists underscores the potential of using natural products to identify new classes of potent and selective ligands and provides new tools to probe the κOR.

Authors

Institutions

Publication Details

Journal
Journal of Medicinal Chemistry
Published
2024-11-20
DOI
https://doi.org/10.1021/acs.jmedchem.4c00736
Citations
3
Primary Topic
Neuropeptides and Animal Physiology
Type
article
Field-Weighted Citation Impact
0.80

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Discovery of Potent Kappa Opioid Receptor Agonists Derived from Akuammicine

José A. Villegas, Anna M. Gutridge, Madeline Hennessy, Lisa E. Rusali et al.
3 citations
Journal of Medicinal Chemistry
Neuropeptides and Animal Physiology
0.80
article

Discovery of Potent Kappa Opioid Receptor Agonists Derived from Akuammicine

José A. Villegas, Anna M. Gutridge, Madeline Hennessy, Lisa E. Rusali, Bakhtyar Sepehri, Simone M. Creed, Andrew P. Riley, Richard M. van Rijn, Elizabeth S. Rhoda, Dan Luo
article en
3 citations

Abstract

Akuammicine (<b>1</b>), an alkaloid isolated from <i>Picralima nitida</i>, is an agonist of the kappa opioid receptor (κOR). To establish structure-activity relationships (SARs) for this structurally unique κOR ligand, a collection of semisynthetic derivatives was synthesized. Evaluating these derivatives for their ability to activate the κOR and mu opioid receptor (μOR) revealed key SAR trends and identified derivatives with enhanced κOR potency. Most notably, substitutions to the C10 position of the aryl ring led to a > 200-fold improvement in κOR potency and nearly complete selectivity for the κOR. A selection of the most potent ligands was shown to possess differing abilities recruitment of β-Arrestin-2 to the κOR, indicating they have distinct signaling properties from each other and existing κOR ligands. The discovery of these κOR agonists underscores the potential of using natural products to identify new classes of potent and selective ligands and provides new tools to probe the κOR.

Journal of Medicinal ChemistryVol. 67(23)
University of Kentucky (US), Purdue University West Lafayette (US), University of Illinois Chicago (US)
American Foundation for Pharmaceutical Education, National Institutes of Health, University of North Carolina at Chapel Hill, National Institute on Alcohol Abuse and Alcoholism, National Institute of Mental Health, National Institute on Drug Abuse, National Institute of General Medical Sciences, National Center for Advancing Translational Sciences, National Center for Complementary and Integrative Health
Openalex Percentile: Top 28%
Neuropeptides and Animal Physiology
0.80
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.